ClinicalTrials.gg
Status unknownNCT05392738Updated Jul 20, 2022

Visual Function and Patient Satisfaction in Glaucoma or Ocular Hypertensive Patients Undergoing Simultaneous Cataract Surgery and i-Stent Implantation

An observational study in Lenses, Intraocular and Glaucoma Filtration Implants, sponsored by Clínica Rementería. Status unknown at 1 site in Spain. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Clínica Rementería · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
40 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.

Planned enrollment
8th of 10
45 · median 365
Started
2022
with 1 other
Observational
10 of 43
3 open now
Registered
34th of 43
by date
Lead sponsor
2 of 43
Clínica Rementería

Among the 43 studies in Glaucoma with a site in Spain, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2022, is one of 10 observational ones, and was the 34th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 40 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma with a site in Spain, or all of them as a file.
02

Study summary

New extended depth of focus intraocular lenses (IOLs) are being used in a broader spectrum of patients than trifocal IOLs. The purpose of this study is to evaluate visual improvement after cataract surgery in patients with glaucoma or ocular hypertension undergoing simultaneous cataract surgery with i-Stent implantation with the implantation of a Vivity IOL. Results will be compared with a group of glaucoma or ocular hypertension undergoing isolated cataract surgery with Vivity implantation, as well as with patients with no pathology undergoing cataract surgery and Vivity implantation

Read the detailed description

The purpose of this study is to report in detail visual function and patient satisfaction, as well as the need for spectacle correction, in patients with glaucoma and ocular hypertension undergoing cataract surgery with bilateral implantation of an extended depth of focus IOL, the Vivity IOL. The study also seeks to determine if there are differences in the speed of visual improvement between patients undergoing isolated cataract surgery and patients undergoing simultaneous i-Stent implantation. Results will also be compared with a group of patients with no ocular pathology undergoing cataract surgery with Vivity implantation.

Patients will be asked to join the study once the type of surgery (isolated phacoemulsification versus phacoemulsification combined with i-Stent implantation) and the type of lens to be implanted (monofocal, EDoF, trifocal) has been agreed between ophthalmologist and patient. Therefore, inclusion in the study will have no influence on surgical indication.

Once informed consent has been signed, the patient will be included in the study.

Explorations specific for the study will be performed 3 and 12 months after surgery and include:

Defocus curves Contrast sensitivity Self-reported photic phenomena Need for spectacle correction Satisfaction measured with the Catquest SF9 questionnaire

Besides study-specific procedures, the following explorations which are standard of care will be performed one day, one week and one month after surgery:

Uncorrected binocular visual acuity for distance, intermediate and near distances Monocular distance corrected and uncorrected visual acuity Residual subjective refraction Slit-lamp examination Intraocular pressure and number of hypotensive drugs required Description of any intra- or postsurgical complications

03

Conditions studied

  • Lenses, Intraocular
  • Glaucoma Filtration Implants

Browse trials for

04

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with glaucoma or ocular hypertension or healthy subjects undergoing bilateral cataract surgery with Vivity intraocular lens implantation with or without i-Stent implantation

Eligibility criteria

Inclusion Criteria: Bilateral cataract surgery with Vivity implantation with or without i_STent implantation

Exclusion Criteria: Ocular disease other than glaucoma

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vivity with i-Stent

    Patients with Glaucoma or Ocular Hypertension undergoing simultaneous cataract and i-Stent implantation, with Vivity intraocular lens

    Device: I-Stent implantation

  • Glaucoma with Vivity

    Patients with Glaucoma or Ocular Hypertension undergoing isolated phacoemulsification with Vivity intraocular lens

  • Healthy with Vivity

    Patients with undergoing isolated phacoemulsification with Vivity intraocular lens

Interventions

  • DeviceI-Stent implantation

    I-Stent implantation

06

What researchers measure

Primary outcomes

  1. Binocular uncorrected distance visual acuity

    Binocular uncorrected distance visual acuity

    Time frame: Three months after surgery

  2. Binocular uncorrected intermediate visual acuity

    Binocular uncorrected intermediate visual acuity

    Time frame: Three months after surgery

  3. Binocular uncorrected near visual acuity

    Binocular uncorrected near visual acuity

    Time frame: Three months after surgery

Secondary outcomes

  1. Binocular uncorrected distance visual acuity

    Binocular uncorrected distance visual acuity

    Time frame: One month after surgery

  2. Binocular uncorrected intermediate visual acuity

    Binocular uncorrected intermediate visual acuity

    Time frame: One month after surgery

  3. Binocular uncorrected near visual acuity

    Binocular uncorrected near visual acuity

    Time frame: One month after surgery

  4. Contrast sensitivity

    Contrast sensitivity

    Time frame: Three months after surgery

  5. Need for spectacle correction

    Need for spectacle correction

    Time frame: Three months after surgery

  6. Patient satisfaction

    Patient satisfaction evaluated with the Catquest SF9 questionnaire

    Time frame: Three months after surgery

07

Study locations

1 site
  • Clínica Rementería
    Madrid, 28010, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.

Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 24 months is below that.

Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Jun 20, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2024
Last update
Jul 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05392738
Lead sponsor
Clínica Rementería
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jun 20, 2022
Primary completion
Jun 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Jul 20, 2022

Study contacts

Beatriz Puerto, MD
principal investigator · Clínica Rementería

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion